- Stocks
- Pharma & Healthcare
- Amanta Healthcare
Amanta Healthcare share price
NSE: AMANTAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Amanta Healthcare at a glance
Amanta Healthcare (NSE: AMANTA) closed at ₹182.55 on 16 Oct 2026. With a market capitalisation of ₹709 Cr, it ranks 1620th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 42.2× trailing earnings, against a return on equity of 10.9% in FY25. Over the past year the share price has risen 37.4%. Its 52-week range is ₹92.00 (16 Mar 2026) to ₹209.95 (10 Sep 2026); the last close is 13.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹69 Cr (+5.3% year on year) and net profit ₹3 Cr (−5.7%), on a standalone basis. Promoters held 63.80% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹709 CrRank 1620 on NSE
- P/E (trailing)
- 42.2×
- Price to book
- 0×FY25
- EPS (TTM)
- ₹4.16to Q1 FY27
- ROE
- 10.9%FY25
- ROCE
- 16.0%FY25
- Debt to equity
- 1.91FY25
- Net profit margin
- 3.8%FY25
- Book value / share
- ₹33.43FY25
- 52-week high
- ₹209.9510 Sep 2026
- 52-week low
- ₹92.0016 Mar 2026
- 1-year return
- +37.4%
- RSI (14-day)
- 45.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.26% | −2.3% | −3.9% | +8.7% | +37.4% |
Amanta Healthcare quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹67 Cr | ₹65 Cr | ₹72 Cr | ₹65 Cr | ₹71 Cr | ₹74 Cr | ₹77 Cr | ₹69 Cr |
| Revenue YoY | — | — | — | −4.1% | +6.2% | +14.3% | +6.8% | +5.3% |
| Net profit | ₹2 Cr | ₹3 Cr | ₹6 Cr | ₹4 Cr | ₹1 Cr | ₹5 Cr | ₹6 Cr | ₹3 Cr |
| Net profit YoY | — | — | — | — | −46.5% | +74.7% | −7.2% | −5.7% |
| Net margin | 3.4% | 4.1% | 8.3% | 5.4% | 1.7% | 6.2% | 7.2% | 4.8% |
| EPS | ₹0.80 | ₹0.94 | ₹2.11 | ₹1.22 | ₹0.35 | ₹1.35 | ₹1.61 | ₹0.85 |
Amanta Healthcare financials
| Item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | ₹259 Cr | ₹280 Cr | ₹275 Cr |
| Operating profit | ₹3 Cr | ₹5 Cr | ₹15 Cr |
| Net profit | −₹2 Cr | ₹4 Cr | ₹11 Cr |
| EPS (₹) | −₹0.79 | ₹1.35 | ₹3.71 |
| Cash from operations | ₹43 Cr | ₹58 Cr | ₹47 Cr |
| Total debt | ₹165 Cr | ₹138 Cr | ₹121 Cr |
| Shareholders' equity | ₹74 Cr | ₹77 Cr | ₹108 Cr |
Amanta Healthcare shareholding pattern
| Holder | 8 Sep 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|
| Promoters | 63.56% | 63.56% | 63.56% | 63.72% | 63.80% |
| Foreign institutions | 2.21% | 1.00% | 1.10% | 0.85% | 0.43% |
| Domestic institutions | 12.22% | 11.34% | 11.24% | 12.88% | 12.92% |
| Non-institutions | 22.02% | 24.10% | 24.10% | 22.56% | 22.85% |
Amanta Healthcare vs peers
The listed Pharma & Healthcare companies nearest to Amanta Healthcare by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
| WANBURYWanbury | ₹185.66 | −0.42% | −25.7% | ₹649 Cr | 9.6 | — |
Ask anything about Amanta Healthcare
Pivot answers on the live chart with evidence you can check, and tests strategies against AMANTA's own history. Try: “Why has AMANTA moved over the last three months?” · “Backtest a 50-day moving-average crossover on AMANTA over five years” · “Compare AMANTA with KILITCH on margins and valuation”
Frequently asked questions about Amanta Healthcare
What is the share price of Amanta Healthcare today?
Amanta Healthcare (NSE: AMANTA) last closed at ₹182.55 on 16 Oct 2026. Its 52-week high is ₹209.95 and its 52-week low is ₹92.00.
What is the market cap of Amanta Healthcare?
Amanta Healthcare's market capitalisation is ₹709 Cr (₹709 Cr) at the 22 Oct 2026 close, ranking 1620th among the NSE companies Pivot tracks.
What is the P/E ratio of Amanta Healthcare?
Amanta Healthcare trades at a trailing P/E of 42.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 24.3.
What is the ROE and ROCE of Amanta Healthcare?
Return on equity was 10.9% in FY25 and return on capital employed was 16.0% in FY25 (standalone figures).
Is Amanta Healthcare a debt-free company?
No. Amanta Healthcare's debt-to-equity ratio was 1.91 in FY25, with total debt of ₹121 Cr.
What were Amanta Healthcare's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Amanta Healthcare reported revenue of ₹69 Cr, +5.3% year on year, and net profit of ₹3 Cr, −5.7% year on year.
How has Amanta Healthcare stock performed over the last year?
Amanta Healthcare's share price has risen 37.4% over the past year, +8.7% over three months and −3.9% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Amanta Healthcare?
As of 30 Jun 2026: promoters 63.80%, foreign institutions 0.43%, domestic institutions 12.92%, non-institutions 22.85%.
Who are Amanta Healthcare's competitors?
The listed Pharma & Healthcare companies closest to Amanta Healthcare by market cap are Kilitch Drugs (India), Vikram Thermo, Zim Laboratories, Valiant Laboratories, Gaudium IVF and Women Health and Wanbury.
Is Amanta Healthcare a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Amanta Healthcare's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AMANTA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 16 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text